0
0

United States Anti-Doping Agency Reauthorization Act of 2021

3/8/2023, 7:58 PM

Summary of Bill HR 172

Bill 117 HR 172, also known as the United States Anti-Doping Agency Reauthorization Act of 2021, is a piece of legislation that aims to reauthorize and provide funding for the United States Anti-Doping Agency (USADA). The USADA is responsible for overseeing drug testing and anti-doping efforts in Olympic and Paralympic sports in the United States.

The bill includes provisions to ensure that the USADA has the necessary resources to continue its important work in promoting clean and fair competition in sports. This includes funding for drug testing programs, education and outreach efforts, and research into new methods of detecting performance-enhancing substances.

Additionally, the bill includes measures to improve transparency and accountability within the USADA. This includes requirements for the agency to report regularly to Congress on its activities and finances, as well as provisions to ensure that athletes have access to a fair and impartial appeals process in cases of alleged doping violations. Overall, the United States Anti-Doping Agency Reauthorization Act of 2021 aims to support the USADA in its mission to protect the integrity of sports and ensure a level playing field for all athletes.

Congressional Summary of HR 172

United States Anti-Doping Agency Reauthorization Act of 2021

This bill authorizes appropriations for the U.S. Anti-Doping Agency (USADA) through FY2030.

The bill adds requirements that USADA

  • be responsible for certifying in advance any testing conducted by international organizations under the World Anti-Doping Code for international amateur athletes and athletic competitions occurring within the jurisdiction of the United States; and
  • promote a positive youth sport experience by using a portion of its funding to provide educational materials on sportsmanship, character building, and healthy performance for those participating in youth sports.

The bill requires any action taken by USADA to enforce a policy, procedure, or requirement against a person with respect to a violation of federal law, including an investigation, disciplinary action, sanction, or any other administrative action, to be carried out in a manner that provides due process protection.

The Department of Justice, the Department of Homeland Security, and the Food and Drug Administration must provide to USADA information relating to the prevention of the use of performance-enhancing drugs or the prohibition of performance-enhancing methods.

Current Status of Bill HR 172

Bill HR 172 is currently in the status of Introduced to Senate since April 15, 2021. Bill HR 172 was introduced during Congress 117 and was introduced to the House on January 4, 2021.  Bill HR 172's most recent activity was Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation. as of April 15, 2021

Bipartisan Support of Bill HR 172

Total Number of Sponsors
1
Democrat Sponsors
1
Republican Sponsors
0
Unaffiliated Sponsors
0
Total Number of Cosponsors
4
Democrat Cosponsors
2
Republican Cosponsors
2
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 172

Primary Policy Focus

Sports and Recreation

Potential Impact Areas

- Alternative dispute resolution, mediation, arbitration
- Athletes
- Child health
- Congressional oversight
- Criminal investigation, prosecution, interrogation
- Drug safety, medical device, and laboratory regulation
- Drug, alcohol, tobacco use
- Due process and equal protection
- International law and treaties
- International organizations and cooperation
- Medical tests and diagnostic methods
- Olympic games

Alternate Title(s) of Bill HR 172

United States Anti-Doping Agency Reauthorization Act of 2021
United States Anti-Doping Agency Reauthorization Act of 2021
United States Anti-Doping Agency Reauthorization Act of 2021
To reauthorize the United States Anti-Doping Agency, and for other purposes.
United States Anti-Doping Agency Reauthorization Act of 2021

Comments